Clinical Trial

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Study acronym: ROXI-EVEREST
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Trial Details
NCT Number NCT07626411
Lead Sponsor Regeneron Pharmaceuticals
Conditions Atrial Fibrillation (AF)
Enrollment 15,364 participants
Start Date 2026-07-31
Primary Completion 2029-09-11 (estimated)
Study Completion 2029-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-04